{"abstract":"The National Center for Advancing Translational Sciences (NCATS), the National Institutes of Health (NIH), is seeking Cooperative Research and Development Agreement (CRADA) partners to collaborate in the final stages of lead optimization, in vitro and in vivo evaluation, and preclinical development of a novel series of potent, selective, and orally bioavailable small molecule agonists of the relaxin hormone receptor, RXFP1, for the treatment of heart failure and fibrosis. Interested potential CRADA collaborators will receive detailed information on the current status of the project after signing a confidentiality disclosure agreement (CDA) with NCATS.","action":null,"agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/02/06/2013-02611.html","cfr_references":[],"citation":"78 FR 8544","comment_url":null,"comments_close_on":"2013-03-08","correction_of":null,"corrections":[],"dates":"Interested candidate partners must submit a statement of interest and capability to the NCATS point of contact before March 8, 2013 for consideration. Guidelines for the preparation of a full CRADA proposal will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest. CRADA applications submitted after the due date may be considered if a suitable CRADA collaborator has not been identified by NIH among the initial pool of respondents. Licensing of background technology related to this CRADA opportunity is also available to potential collaborators.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2013-02611","effective_on":null,"end_page":8546,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/02/06/2013-02611.xml","html_url":"https://www.federalregister.gov/documents/2013/02/06/2013-02611/national-center-for-advancing-translational-sciences-ncats-cooperative-research-and-development","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-02611?publication_date=2013-02-06","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-02-06/2013-02611/mods.xml","not_received_for_publication":null,"page_length":3,"page_views":{"count":553,"last_updated":"2026-08-25 20:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-02-06/pdf/2013-02611.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-02611.pdf?1360072598","publication_date":"2013-02-06","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/02/06/2013-02611.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2013-03-10T05:00:17Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":8544,"subtype":null,"title":"National Center for Advancing Translational Sciences (NCATS): Cooperative Research and Development Agreement (CRADA) and Licensing Opportunity for Small Molecule Agonists of the Relaxin Hormone Receptor (RXFP1) for Treatment of Heart Failure and Fibrosis","toc_doc":"Small Molecule Agonists of Relaxin Hormone Receptor for Treatment of Heart Failure and Fibrosis","toc_subject":"Cooperative Research and Development Agreements and Licensing Opportunities:","topics":[],"type":"Notice","volume":78}